The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Tatjana Antic and Melissa Tjota.
Connection Strength

5.675
  1. Papillary renal cell carcinoma, formerly known as Type 2: a single institutional study addressing histologic and molecular features. Histopathology. 2026 Apr; 88(5):1044-1050.
    View in: PubMed
    Score: 0.947
  2. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Hum Pathol. 2023 04; 134:124-133.
    View in: PubMed
    Score: 0.771
  3. Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case. Pathology. 2021 Oct; 53(6):790-793.
    View in: PubMed
    Score: 0.675
  4. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study. Hum Pathol. 2021 09; 115:84-95.
    View in: PubMed
    Score: 0.670
  5. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study. Am J Surg Pathol. 2020 07; 44(7):943-954.
    View in: PubMed
    Score: 0.648
  6. Clinicopathological and molecular comparison of eosinophilic solid and cystic renal cell carcinoma and TFEB-amplified renal cell carcinoma: a comprehensive study of 15 cases. Histopathology. 2026 Aug 13.
    View in: PubMed
    Score: 0.248
  7. Comprehensive analysis of six MED15::TFE3 renal cell carcinomas including two novel solid MED15::TFE3 renal cell carcinomas, highlighting their morphologic, immunohistochemical and molecular differences from their cystic counterparts. Virchows Arch. 2026 Sep; 489(3):669-680.
    View in: PubMed
    Score: 0.243
  8. MTOR-mutated eosinophilic renal cell carcinomas with loss of chromosome 1 and high metastatic potential: further expanding the spectrum of TSC/mTOR pathway mutated renal tumors. Virchows Arch. 2026 Sep; 489(3):575-581.
    View in: PubMed
    Score: 0.236
  9. Renal Tumorigenesis via RAS/RAF/MAPK Pathway Alterations Beyond Papillary Renal Neoplasm With Reverse Polarity. Am J Surg Pathol. 2025 Dec 01; 49(12):1266-1278.
    View in: PubMed
    Score: 0.229
  10. Primary Melanoma of the Lung: A Vanishing Entity. Acta Cytol. 2025; 69(4):361-366.
    View in: PubMed
    Score: 0.227
  11. GATA3 Expression in Solid Vimentin-Negative Eosinophilic Renal Epithelial Tumors-A Comprehensive Study of 48 Tumors. Int J Surg Pathol. 2025 Jun; 33(4):820-827.
    View in: PubMed
    Score: 0.219
  12. Oncocytoma-Like Angiomyolipoma of the Kidney: A Closer Look into the Clinicopathologic, Immunohistochemical, and Molecular Characteristics of a Rare Entity with Review of the Literature. Int J Surg Pathol. 2024 May; 32(3):625-631.
    View in: PubMed
    Score: 0.200
  13. NF2-mutated Renal Carcinomas Have Common Morphologic Features Which Overlap With Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma: A Comprehensive Study of 14 Cases. Am J Surg Pathol. 2022 05 01; 46(5):617-627.
    View in: PubMed
    Score: 0.184
  14. Penile squamous cell carcinomas with the usual-type morphology can be HPV-associated - Routine p16/HPV testing should be performed in all penile squamous cell carcinomas regardless of morphology. Virchows Arch. 2026 Jun 24.
    View in: PubMed
    Score: 0.061
  15. NFE2L2-mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD-L1 expression. Histopathology. 2026 Jun 06.
    View in: PubMed
    Score: 0.061
  16. Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1/TSC2-Mutations: A Series of 4 cases and a review of the literature. Hum Pathol. 2024 Nov; 153:105680.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.